Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer Angiochem.

Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer Angiochem, Inc. A clinical-stage biotechnology firm developing drugs that are capable of crossing the blood-mind barrier to treat brain diseases uniquely, announced today that its lead drug candidate, ANG1005, has demonstrated a good safety and efficacy account in more than 100 patients with brain tumor from two separate Stage 1 /2 clinical studies in sufferers with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases tablet super cialisinorge.com .

Other Posts From "treatments":

Related Posts